These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
217 related items for PubMed ID: 15585639
1. Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs. Dandekar DS, Lokeshwar BL. Clin Cancer Res; 2004 Dec 01; 10(23):8037-47. PubMed ID: 15585639 [Abstract] [Full Text] [Related]
2. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Dandekar DS, Lopez M, Carey RI, Lokeshwar BL. Int J Cancer; 2005 Jun 20; 115(3):484-92. PubMed ID: 15688368 [Abstract] [Full Text] [Related]
3. In vitro and in vivo inhibitory effect evaluation of cyclooxygenase-2 inhibitors, antisense cyclooxygenase-2 cDNA, and their combination on the growth of human bladder cancer cells. Qin J, Yuan J, Li L, Liu H, Qin R, Qin W, Chen B, Wang H, Wu K. Biomed Pharmacother; 2009 Mar 20; 63(3):241-8. PubMed ID: 18617357 [Abstract] [Full Text] [Related]
4. Cyclooxygenase-2 promotes prostate cancer progression. Fujita H, Koshida K, Keller ET, Takahashi Y, Yoshimito T, Namiki M, Mizokami A. Prostate; 2002 Nov 01; 53(3):232-40. PubMed ID: 12386924 [Abstract] [Full Text] [Related]
5. Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer. Leonetti C, Biroccio A, D'Angelo C, Semple SC, Scarsella M, Zupi G. Prostate; 2007 Sep 15; 67(13):1475-85. PubMed ID: 17654511 [Abstract] [Full Text] [Related]
6. Antisense protein kinase A RIalpha acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: molecular basis for combinatorial therapy. Cho YS, Cho-Chung YS. Clin Cancer Res; 2003 Mar 15; 9(3):1171-8. PubMed ID: 12631623 [Abstract] [Full Text] [Related]
7. Age-associated changes in the expression pattern of cyclooxygenase-2 and related apoptotic markers in the cancer susceptible region of rat prostate. Badawi AF, Liu Y, Eldeen MB, Morrow W, Razak ZR, Maradeo M, Badr MZ. Carcinogenesis; 2004 Sep 15; 25(9):1681-8. PubMed ID: 15117812 [Abstract] [Full Text] [Related]
8. Protein kinase A RIalpha antisense inhibition of PC3M prostate cancer cell growth: Bcl-2 hyperphosphorylation, Bax up-regulation, and Bad-hypophosphorylation. Cho YS, Kim MK, Tan L, Srivastava R, Agrawal S, Cho-Chung YS. Clin Cancer Res; 2002 Feb 15; 8(2):607-14. PubMed ID: 11839683 [Abstract] [Full Text] [Related]
9. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Liu XH, Yao S, Kirschenbaum A, Levine AC. Cancer Res; 1998 Oct 01; 58(19):4245-9. PubMed ID: 9766645 [Abstract] [Full Text] [Related]
10. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Cancer Res; 1998 Jan 15; 58(2):362-6. PubMed ID: 9443418 [Abstract] [Full Text] [Related]
11. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Miyake H, Nelson C, Rennie PS, Gleave ME. Cancer Res; 2000 May 01; 60(9):2547-54. PubMed ID: 10811138 [Abstract] [Full Text] [Related]
12. Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models. Festuccia C, Gravina GL, D'Alessandro AM, Muzi P, Millimaggi D, Dolo V, Ricevuto E, Vicentini C, Bologna M. Endocr Relat Cancer; 2009 Jun 01; 16(2):401-13. PubMed ID: 19153211 [Abstract] [Full Text] [Related]
15. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. Song X, Lin HP, Johnson AJ, Tseng PH, Yang YT, Kulp SK, Chen CS. J Natl Cancer Inst; 2002 Apr 17; 94(8):585-91. PubMed ID: 11959891 [Abstract] [Full Text] [Related]
16. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Sun Y, Tang XM, Half E, Kuo MT, Sinicrope FA. Cancer Res; 2002 Nov 01; 62(21):6323-8. PubMed ID: 12414664 [Abstract] [Full Text] [Related]
17. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway. Yasumaru M, Tsuji S, Tsujii M, Irie T, Komori M, Kimura A, Nishida T, Kakiuchi Y, Kawai N, Murata H, Horimoto M, Sasaki Y, Hayashi N, Kawano S, Hori M. Cancer Res; 2003 Oct 15; 63(20):6726-34. PubMed ID: 14583467 [Abstract] [Full Text] [Related]
18. Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model. Sakai I, Miyake H, Terakawa T, Fujisawa M. Cancer Sci; 2011 Apr 15; 102(4):769-75. PubMed ID: 21214673 [Abstract] [Full Text] [Related]
19. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Patel MI, Subbaramaiah K, Du B, Chang M, Yang P, Newman RA, Cordon-Cardo C, Thaler HT, Dannenberg AJ. Clin Cancer Res; 2005 Mar 01; 11(5):1999-2007. PubMed ID: 15756026 [Abstract] [Full Text] [Related]
20. Cyclooxygenase-2 in cancer cells and macrophages induces colon cancer cell growth by cigarette smoke extract. Liu ES, Shin VY, Ye YN, Luo JC, Wu WK, Cho CH. Eur J Pharmacol; 2005 Jul 25; 518(1):47-55. PubMed ID: 15993407 [Abstract] [Full Text] [Related] Page: [Next] [New Search]